Revista Portuguesa De Cardiologia最新文献

英文中文

Echoes of Uncertainty: A Cardiac Mass in Focus. 不确定性的回声：聚焦的心脏肿块。

IF 1.6 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Revista Portuguesa De Cardiologia

Pub Date : 2026-02-03 DOI: 10.1016/j.repc.2025.12.005

Catarina Gregório, Daniel Cazeiro, Ana Margarida Martins, Raquel Vaz, Tânia Vassalo, Joana Rigueira, Catarina Sousa, Fausto J Pinto, Rui Plácido

引用次数: 0

Reversal of left bundle branch block and recovery of left ventricular dysfunction by left bundle branch area pacing in a patient with left bundle branch block-induced cardiomyopathy. 左束支阻滞致心肌病患者左束支区起搏逆转左束支阻滞及恢复左室功能障碍1例。

IF 1.6 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Revista Portuguesa De Cardiologia

Pub Date : 2026-02-02 DOI: 10.1016/j.repc.2025.10.008

Zhengyu Lin, Xinyin Xie, Hui Zeng, Xuanyan Zhong, Min Yu

引用次数: 0

Association between sarcopenia and quality of life in patients with heart failure 心力衰竭患者肌肉减少症与生活质量的关系

IF 1.6 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Revista Portuguesa De Cardiologia

Pub Date : 2026-02-01 DOI: 10.1016/j.repc.2025.09.008

Leonor P. Silva , Luciana Silva , Inês Neves , Inês Soares , Raquel Moura , Diana Lucas , Catarina Pereira , Tiago Gregório , Joana Pimenta , Joana Mascarenhas

Introduction and objectives

Sarcopenia, which is characterized by the loss of skeletal muscle mass and function, is prevalent among patients with heart failure (HF) and negatively impacts their quality of life (QoL). The purpose of this study was to test the hypothesis that reduced muscle strength, as measured by handgrip strength (HGS), is independently associated with poorer quality of life (QoL) in patients with heart failure (HF).

Methods

This cross-sectional study involved 114 patients with stable HF. HGS was assessed through a digital dynamometer; sarcopenia was defined by using gender-specific thresholds. Additional assessments included demographics, comorbidities, HF severity, frailty and QoL (the Kansas City Cardiomyopathy Questionnaire was used as a tool). To determine factors independently associated with QoL, a multiple linear regression model was obtained; we also derived a stepwise multiple linear regression model based on the Akaike Information Criteria.

Results

Average HGS was 20.9±8.4 kg and 54.5% of patients were classified as having probable sarcopenia. HGS demonstrated a positive correlation with QoL (r=0.46, p<0.001) and negative correlation with the New York Heart Association classification and the Clinical Frailty Scale. Multivariate analysis revealed that a higher HGS, a younger age, a lower NYHA class and lower frailty scores were significantly associated with a better QoL. A 10 kg increase in HGS was associated with an 8.7-point rise in KCCQ-23 scores.

Conclusion

Handgrip strength is an independent predictor of QoL in patients with chronic HF. A regular assessment of HGS in clinical practice may help monitor the risk of sarcopenia and improve patient management, potentially enhancing daily functioning and QoL.

**简介与目的：**骨骼肌减少症是一种以骨骼肌质量和功能丧失为特征的疾病，在心力衰竭（HF）患者中普遍存在，并对其生活质量（QoL）产生负面影响。本研究的目的是验证一个假设，即通过握力（HGS）测量的肌肉力量减少与心力衰竭（HF）患者的生活质量（QoL）较差独立相关。方法：对114例稳定型心衰患者进行横断面研究。HGS通过数字测功机进行评估；骨骼肌减少症的定义采用性别特异性阈值。其他评估包括人口统计学、合并症、HF严重程度、虚弱和生活质量（使用堪萨斯城心肌病问卷作为工具）。为了确定与生活质量独立相关的因素，建立了多元线性回归模型；并基于赤池信息准则建立了逐步多元线性回归模型。结果：平均HGS为20.9±8.4 kg， 54.5%的患者为可能的肌肉减少症。HGS与生活质量呈正相关（r = 0.46, p）。结论：握力是慢性HF患者生活质量的独立预测因子。在临床实践中定期评估HGS可能有助于监测肌肉减少症的风险，改善患者管理，潜在地提高日常功能和生活质量。

{"title":"Association between sarcopenia and quality of life in patients with heart failure","authors":"Leonor P. Silva , Luciana Silva , Inês Neves , Inês Soares , Raquel Moura , Diana Lucas , Catarina Pereira , Tiago Gregório , Joana Pimenta , Joana Mascarenhas","doi":"10.1016/j.repc.2025.09.008","DOIUrl":"10.1016/j.repc.2025.09.008","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Sarcopenia, which is characterized by the loss of skeletal muscle mass and function, is prevalent among patients with heart failure (HF) and negatively impacts their quality of life (QoL). The purpose of this study was to test the hypothesis that reduced muscle strength, as measured by handgrip strength (HGS), is independently associated with poorer quality of life (QoL) in patients with heart failure (HF).</div></div><div><h3>Methods</h3><div>This cross-sectional study involved 114 patients with stable HF. HGS was assessed through a digital dynamometer; sarcopenia was defined by using gender-specific thresholds. Additional assessments included demographics, comorbidities, HF severity, frailty and QoL (the Kansas City Cardiomyopathy Questionnaire was used as a tool). To determine factors independently associated with QoL, a multiple linear regression model was obtained; we also derived a stepwise multiple linear regression model based on the Akaike Information Criteria.</div></div><div><h3>Results</h3><div>Average HGS was 20.9±8.4 kg and 54.5% of patients were classified as having probable sarcopenia. HGS demonstrated a positive correlation with QoL (r=0.46, p<0.001) and negative correlation with the New York Heart Association classification and the Clinical Frailty Scale. Multivariate analysis revealed that a higher HGS, a younger age, a lower NYHA class and lower frailty scores were significantly associated with a better QoL. A 10 kg increase in HGS was associated with an 8.7-point rise in KCCQ-23 scores.</div></div><div><h3>Conclusion</h3><div>Handgrip strength is an independent predictor of QoL in patients with chronic HF. A regular assessment of HGS in clinical practice may help monitor the risk of sarcopenia and improve patient management, potentially enhancing daily functioning and QoL.</div></div>","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 2","pages":"Pages 69-76"},"PeriodicalIF":1.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145726831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Turning the heart around: Pacemaker implantation in situs inversus 心脏转个身：起搏器植入逆位。

IF 1.6 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Revista Portuguesa De Cardiologia

Pub Date : 2026-02-01 DOI: 10.1016/j.repc.2025.08.009

Joana Certo Pereira , Isabel Santos , Francisco Gama , Pedro Adragão

引用次数: 0

Lipid-lowering therapy and LDL cholesterol control among high- and very high-risk patients in Portugal: An analysis of the SANTORINI study 降脂治疗和低密度脂蛋白胆固醇控制在葡萄牙的高风险和高危患者：圣托里尼研究的分析。

IF 1.6 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Revista Portuguesa De Cardiologia

Pub Date : 2026-02-01 DOI: 10.1016/j.repc.2025.10.003

Carlos Aguiar , Patrício Aguiar , João Sequeira Duarte , Victor Gil , Jorge Mimoso , Pedro Monteiro , Fausto J. Pinto , Fernando Pinto , João Raposo , Pedro von Hafe , Jorge A. Ruivo , Carla Teixeira , Alberico L. Catapano , Kausik K. Ray

Introduction and objectives

The SANTORINI study is the first large-scale, European observational study conducted following the release of the 2019 European Society of Cardiology/European Atherosclerosis Society ESC/EAS guidelines on dyslipidemia management. This analysis aims to assess lipid-lowering therapy (LLT) use and low-density lipoprotein cholesterol (LDL-C) goal attainment in patients at high or very high cardiovascular (CV) risk enrolled in Portugal.

Methods

In Portugal, 117 patients were enrolled across 10 sites between September 2020 and February 2021. Paired LDL-C values at baseline and one-year follow-up were available for 102 patients. LDL-C levels, LLT utilization patterns, and LDL-C goal attainment (as per the 2019 ESC/EAS guidelines) were assessed at both time points and compared with the broader European cohort, excluding Portuguese participants.

Results

Over the one-year follow-up, the use of statin monotherapy decreased from 49.5% to 45.2%, while combination therapy with statin and ezetimibe increased from 35.9% to 40.9%. LLT intensity was escalated in 12.8% of patients, unchanged in 79.5%, and de-escalated in 6.0%. Mean LDL-C levels were similar between baseline and one-year follow-up: corresponding values were 90.2 mg/dL and 90.1 mg/dL in high-risk patients, and 74.1 mg/dL and 75.2 mg/dL in very high-risk patients. LDL-C goal attainment declined from 34.1% to 22.7% in high-risk patients and 27.6% to 22.4% in very high-risk patients.

Conclusions

The Portuguese cohort of the SANTORINI study demonstrates both encouraging developments and ongoing challenges in the real-world management of dyslipidemia following the 2019 ESC/EAS guidelines. Reasons for lack of LLT intensification and factors underlying worsening rates for LDL-C goal attainment should be explored.

简介和目的：SANTORINI研究是2019年欧洲心脏病学会/欧洲动脉粥样硬化学会ESC/EAS关于血脂异常管理指南发布后进行的第一个大规模欧洲观察性研究。本分析旨在评估降脂治疗（LLT）的使用和低密度脂蛋白胆固醇（LDL-C）目标在葡萄牙注册的高或非常高心血管（CV）风险患者中的实现情况。方法：在葡萄牙，2020年9月至2021年2月期间，在10个地点招募了117名患者。102例患者基线和1年随访时的配对LDL-C值。在两个时间点评估LDL-C水平、LLT利用模式和LDL-C目标实现情况（根据2019年ESC/EAS指南），并与更广泛的欧洲队列（不包括葡萄牙参与者）进行比较。结果：在1年的随访中，他汀类药物单药使用率从49.5%下降到45.2%，而他汀类药物与依折替米贝联用使用率从35.9%上升到40.9%。12.8%的患者LLT强度升高，79.5%的患者强度不变，6.0%的患者强度降低。基线和一年随访期间的平均LDL-C水平相似：高危患者相应值为90.2 mg/dL和90.1 mg/dL，高危患者相应值为74.1 mg/dL和75.2 mg/dL。高危患者LDL-C目标达标率从34.1%下降到22.7%，高危患者从27.6%下降到22.4%。结论：SANTORINI的葡萄牙队列研究显示，在遵循2019年ESC/EAS指南的实际血脂异常管理中，既有令人鼓舞的发展，也存在持续的挑战。应探讨缺乏LLT强化的原因和LDL-C目标达成率恶化的潜在因素。

{"title":"Lipid-lowering therapy and LDL cholesterol control among high- and very high-risk patients in Portugal: An analysis of the SANTORINI study","authors":"Carlos Aguiar , Patrício Aguiar , João Sequeira Duarte , Victor Gil , Jorge Mimoso , Pedro Monteiro , Fausto J. Pinto , Fernando Pinto , João Raposo , Pedro von Hafe , Jorge A. Ruivo , Carla Teixeira , Alberico L. Catapano , Kausik K. Ray","doi":"10.1016/j.repc.2025.10.003","DOIUrl":"10.1016/j.repc.2025.10.003","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>The SANTORINI study is the first large-scale, European observational study conducted following the release of the 2019 European Society of Cardiology/European Atherosclerosis Society ESC/EAS guidelines on dyslipidemia management. This analysis aims to assess lipid-lowering therapy (LLT) use and low-density lipoprotein cholesterol (LDL-C) goal attainment in patients at high or very high cardiovascular (CV) risk enrolled in Portugal.</div></div><div><h3>Methods</h3><div>In Portugal, 117 patients were enrolled across 10 sites between September 2020 and February 2021. Paired LDL-C values at baseline and one-year follow-up were available for 102 patients. LDL-C levels, LLT utilization patterns, and LDL-C goal attainment (as per the 2019 ESC/EAS guidelines) were assessed at both time points and compared with the broader European cohort, excluding Portuguese participants.</div></div><div><h3>Results</h3><div>Over the one-year follow-up, the use of statin monotherapy decreased from 49.5% to 45.2%, while combination therapy with statin and ezetimibe increased from 35.9% to 40.9%. LLT intensity was escalated in 12.8% of patients, unchanged in 79.5%, and de-escalated in 6.0%. Mean LDL-C levels were similar between baseline and one-year follow-up: corresponding values were 90.2 mg/dL and 90.1 mg/dL in high-risk patients, and 74.1 mg/dL and 75.2 mg/dL in very high-risk patients. LDL-C goal attainment declined from 34.1% to 22.7% in high-risk patients and 27.6% to 22.4% in very high-risk patients.</div></div><div><h3>Conclusions</h3><div>The Portuguese cohort of the SANTORINI study demonstrates both encouraging developments and ongoing challenges in the real-world management of dyslipidemia following the 2019 ESC/EAS guidelines. Reasons for lack of LLT intensification and factors underlying worsening rates for LDL-C goal attainment should be explored.</div></div>","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 2","pages":"Pages 51-64"},"PeriodicalIF":1.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145649842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early surgical management of neonatal coronary artery fistula with severe hemodynamic impact 新生儿冠状动脉瘘伴严重血流动力学影响的早期手术治疗。

IF 1.6 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Revista Portuguesa De Cardiologia

Pub Date : 2026-02-01 DOI: 10.1016/j.repc.2025.09.009

Catarina Cezanne , Isabel Graça , Tomas Sim Sim , Carla Saraiva , Ana Rita Araújo , João Rato , Marta Marques , Mónica Rebelo

引用次数: 0

Closing the LDL-C gap: Lessons from the Portuguese SANTORINI subanalysis 缩小LDL-C差距：来自葡萄牙圣托里尼亚分析的教训

IF 1.6 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Revista Portuguesa De Cardiologia

Pub Date : 2026-02-01 DOI: 10.1016/j.repc.2026.01.003

Ricardo Fontes-Carvalho

引用次数: 0

Response to “Insights on effectiveness of a cardiac rehabilitation program in women with heart failure” 对“对心力衰竭妇女心脏康复计划有效性的见解”的回应。

IF 1.6 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Revista Portuguesa De Cardiologia

Pub Date : 2026-02-01 DOI: 10.1016/j.repc.2025.12.001

Andreia Campinas

引用次数: 0

The first year of generic non-vitamin K oral anticoagulants: Implications for patients and the healthcare system 非维生素K类口服抗凝剂的第一年：对患者和医疗保健系统的影响。

IF 1.6 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Revista Portuguesa De Cardiologia

Pub Date : 2026-02-01 DOI: 10.1016/j.repc.2025.10.004

Rita Barbosa Sousa , Afonso Félix de Oliveira , Eduardo Infante de Oliveira

引用次数: 0

Insights on “Effectiveness of a cardiac rehabilitation program in women with heart failure” 关于“心力衰竭妇女心脏康复计划的有效性”的见解。

IF 1.6 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Revista Portuguesa De Cardiologia

Pub Date : 2026-02-01 DOI: 10.1016/j.repc.2025.11.005

Parth Aphale, Himanshu Shekhar, Shashank Dokania

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Revista Portuguesa De Cardiologia

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀